Attached files
| file | filename |
|---|---|
| 8-K - 8-K - HAEMONETICS CORP | haeq3dec2015form8-k.htm |
Exhibit 99.1 | |||
News Release | |||
FOR RELEASE: | CONTACT: | ||
Date | January 29, 2015 | Gerry Gould, VP-Investor Relations | |
Time | 8:00 am Eastern | Tel. (781) 356-9402 | |
gerry.gould@haemonetics.com | |||
Alt. (781) 356-9613 | |||
Haemonetics Reports 3rd Quarter Fiscal 2015 Revenue of $232 Million and Adjusted EPS of $0.53; Reaffirms Revenue and EPS Guidance
Braintree, MA, January 29, 2015 - Haemonetics Corporation (NYSE: HAE) today reported third quarter fiscal 2015 revenue of $231.8 million, down 4.3%. In constant currency, revenue declined 1.4% in the quarter. The Company reported third quarter GAAP net income of $16.0 million and GAAP net income per share of $0.31. Exclusive of transformation, restructuring and deal amortization expenses detailed below, adjusted net income was $27.5 million and adjusted earnings per share were $0.53, both down 14%.1
For the first three quarters of fiscal 2015, revenue was $683.9 million, down 2% as reported and 1% in constant currency. The Company reported year-to-date GAAP net income of $19.8 million and GAAP net income per share of $0.38. Exclusive of transformation, restructuring and deal amortization expenses detailed below, adjusted net income was $71.6 million, down 21%, and adjusted earnings per share were $1.38, down 20%.1
3Q FISCAL 2015 HIGHLIGHTS
• | Solid constant currency revenue increases in growth drivers including: |
▪ | 11% growth in plasma disposables revenue |
▪ | 25% growth in TEG® diagnostics disposables revenue |
▪ | 11% growth in China disposables revenue |
• | Key new product advances |
▪ | TEG 6s diagnostics device received two 510(k) clearances |
▪ | SOLX® clinical trial data submitted to the FDA |
▪ | Signed first Comprehensive Blood Management Solutions (CBMS) account targeting significant economic value for the Hospital through BloodTrack® HaemoBank™, TEG, cell salvage, SafeTrace TX® and other Company software and service offerings |
▪ | Secured second customer for next generation Plasma software |
• | Value Creation and Capture (“VCC”) initiatives continuing on schedule with February 5 “ribbon cutting” planned for new Penang, Malaysia plant |
GROWTH DRIVERS UPDATE
Combined constant currency disposables revenue increase for the Company’s growth drivers of Plasma, TEG and Emerging Markets was 7% in the third quarter. Orders in emerging markets were impacted by economic weakness in Russia, where revenue was lower than in the prior year quarter, adversely impacting the disposables revenue growth rate for the combined growth drivers by 2%. On a constant currency basis, these growth drivers had 10% disposables growth in the first nine months of fiscal 2015, and 8% when adjusted for the impact of a favorable Plasma comparison resulting from the acquisition of the Company’s Australian plasma distributor in the same period of fiscal 2014.
The Company announced that its next generation diagnostics device, the TEG 6s, recently received the first two of three required 510(k) clearances. The Company expects to begin a limited market release in the U.S. early in fiscal 2016.
The Company announced it has completed the planned clinical testing of its SOLX storage solution, submitted final data to the FDA, and filed for Canadian registration of SOLX. Plans are being formulated to introduce SOLX, together with the Company’s whole blood filter, in a North American limited market release, upon receipt of required clearances.
The Company also announced that KEDPlasma USA has gone live with Haemonetics’ next generation donor management software, representing the second long-term customer contract for this software, which recently received 510(k) approval.
Brian Concannon, Haemonetics’ President and CEO, stated: “Our growth drivers, which represent 60% of our disposables revenue in the third quarter, continue to deliver solid growth despite headwinds resulting from economic uncertainty in the Russian market. We expect this strong revenue performance to continue, bolstered by recent Plasma contract wins.
“In fiscal 2016, the expected continued strong performance of our growth drivers and the anniversary of much of the headwind experienced in our North American whole blood business during fiscal 2015, underpin our outlook for a return to mid-single digit revenue growth.”
THIRD QUARTER AND YEAR-TO-DATE 2015 REVENUE ELEMENTS
Plasma
Plasma disposables revenue was $83.2 million in the third quarter, up $6.5 million, or 8% on a reported basis and 11% in constant currency. North America Plasma disposables revenue was up 13%, as collection volumes continued to benefit from a robust end user market for plasma-derived biopharmaceuticals. Excluding the favorable impact of the distribution model change in Australia last year, Plasma revenue growth was 11% in the first nine months of 2015.
Blood Center
Platelet disposables revenue was $38.4 million in the third quarter, down 12% on a reported basis, and down 4% on a constant currency basis. Year-to-date constant currency revenue growth of 4% was attributable to strong demand in emerging markets.
Red cell disposables revenue was $10.9 million in the third quarter, up 10%, and $31.3 million year-to-date, up 4% over the prior year. Growth was principally in North America and resulted from changes in red cell collection practices and favorable comparisons with the prior year.
Whole blood disposables revenue was $34.2 million in the third quarter of fiscal 2015, down 28%, and $105.9 million year-to-date, down 27%. Previously disclosed market share losses, pricing and the termination of an OEM supply contract negotiated at the time of the whole blood acquisition contributed to the declines. These headwinds will anniversary by the end of the first quarter of fiscal 2016. Declines in North American transfusion rates of roughly 10% contributed approximately $6 million of the year-to-date decline. This trend is expected to continue through the remainder of fiscal 2015 and then moderate in fiscal 2016.
Hospital
Surgical disposables revenue was $15.6 million in the third quarter, down 7% as reported and down 1% on a constant currency basis. Year-to-date fiscal 2015 surgical disposals revenue of $46.9 million was down 5% as reported and 2% in constant currency. Strength in the emerging markets was offset by declines in the developed markets in the third quarter and first nine months.
Disposables revenue from the OrthoPAT® orthopedic perioperative autotransfusion system was $5.0 million for the quarter, down 21%. Year-to-date OrthoPAT
revenue was $15.3 million, down 19%. Market trends toward the adoption of tranexamic acid to prevent post-operative blood loss continued to lessen hospital use of OrthoPAT disposables.
Diagnostics disposables revenue was $10.9 million for the quarter, up 27%. Year to date diagnostics disposables revenue was $30.5 million, up 26%. The TEG Hemostasis Analyzer installed base increased 15% in the trailing 12 months, positioning the TEG business for continued double-digit disposables revenue growth.
Software and Equipment
Software Solutions revenue was $18.2 million in the third quarter, up $0.6 million, and $54.1 million year-to-date, up $2.6 million, a 3% increase in the quarter and 5% year-to-date. BloodTrack, a key enabler of the Company’s CBMS growth strategy, drove much of this growth and the pipeline for blood management software opportunities remains strong.
Equipment and other revenue was $15.5 million, essentially flat with the prior year’s third quarter. Equipment revenue is influenced by timing of tenders and capital budgets. The installed base of equipment, including devices sold and placed for use with customers, increased 5% in the first nine months of fiscal 2015 and 8% in the last 12 months.
Geographic
In the third quarter of fiscal 2015, Haemonetics announced revenue growth of 5% in Asia Pacific and declines of 2% in North America, 7% in Europe and 18% in Japan on a reported basis. On a constant currency basis, the Company had revenue growth of 6% in Asia Pacific and 2% in Japan, with declines of 2% in North America and 5% in Europe.
Growth in Asia Pacific reflects continued strength in China. In North America, growth in Plasma, TEG diagnostics and software were more than offset by declines in the Blood Center business. Weakness in Russia contributed to declines in Europe. Weakness in Japan was attributable to the Yen exchange rate.
OPERATING RESULTS
Adjusted gross profit was $114.1 million, down $10.1 million from the prior year third quarter and included a $2.3 million unfavorable currency impact. Adjusted gross margin was 49.2%, down 210 basis points from the prior year’s quarter but up sequentially 60 basis points over the adjusted gross margin in the first half of the fiscal year. Lower U.S. whole blood disposables pricing, lower volume in certain manufacturing facilities and product mix contributed to the year over year decline.
Adjusted operating expenses were $75.7 million in the quarter, down $6.0 million or 7% over the prior year third quarter. Critical investments continued and were more than offset by organizational and corporate administrative cost reductions.
In the third quarter, adjusted operating income was $38.4 million, down $4.1 million or 10%, reflecting the gross margin headwinds cited. Adjusted operating margin in the quarter was 16.6%, down 90 basis points from the prior year’s quarter but up sequentially 250 basis points over the adjusted operating margin in the first half of the fiscal year.
Adjusted interest expense on loans was $2.0 million. The adjusted income tax rate was 24.4% compared with 19.6% in the prior year third quarter, as the prior year third quarter benefited from the expiration of certain tax statutes. For the full year, the tax rate is expected to approximate 25%.
Mr. Concannon said: “As we approach the end of this transitional year, we are encouraged with continued progress in our growth drivers and cost management programs which are contributing to the sequential recovery of our gross and operating margins.
“Despite the ongoing headwinds related to the strength of the U.S. dollar and uncertainties in the Russian market, we are reaffirming our fiscal 2015 revenue and earnings per share guidance.”
BALANCE SHEET AND CASH FLOW
Cash on hand was $125 million, a decrease of $67 million during the first nine months of fiscal 2015. The Company’s free cash flow, before transformation and restructuring costs, was $53 million, a decrease of $42 million compared with the first nine months of fiscal 2014.
During the first nine months of fiscal 2015, the Company utilized $81 million, net of cash tax benefits, to fund VCC and other restructuring initiatives, $39 million to repurchase shares in the open market and $10 million to repay debt.
FISCAL 2015 SHARE REPURCHASE PROGRAM
The Company repurchased 1,165,100 shares in the open market at an average price of $33.22, for a total spend of $39 million in the first three quarters of fiscal 2015. As previously announced, the Board of Directors approved the repurchase of up to $100 million of shares in the open market.
VALUE CREATION & CAPTURE ACTIVITIES
Plans to pursue identified Value Creation & Capture (“VCC”) opportunities, designed principally to transform the Company’s manufacturing and distribution operations, and to support its productivity and commercial excellence initiatives, continue to progress according to schedule. The recent completion of the Company’s Penang Malaysia facility is the latest in a series of major accomplishments related to the three year VCC program.
VCC investments are still expected to approximate $160 million in total and to generate approximately $60-$65 million of annual cost savings by fiscal 2018. The planned investments and expected benefits are summarized in a schedule posted to the Company’s Investor Relations website at http://phx.corporate-ir.net/phoenix.zhtml?c=72118&p=irol-guidance.
FISCAL 2015 GUIDANCE
Overall fiscal 2015 revenue guidance is reaffirmed at a decline of 0-2%, with revenue growth from identified growth drivers more than offset by revenue headwind from net volume and pricing declines in the U.S. blood center business, increased Japanese Yen weakness and worsening economic conditions in Russia.
Fiscal 2015 guidance for Plasma disposables revenue growth is increased to 9-11% from the previous range of 7-9% growth, while hospital disposables revenue is now expected to grow 0-2% versus a previous guidance range of 4-6%. The Company reaffirmed prior guidance ranges for blood center disposables revenue to decline 10-12% and Software Solutions growth of 2-4%.
Full year expectations for adjusted gross margin are approximately 49%, below the prior estimate of 50%, as higher Plasma and lower Hospital revenue guidance
represents unfavorable gross margin mix. Adjusted earnings per share in the range of $1.85 to $1.95 are reaffirmed.
Previous free cash flow guidance of approximately $100-$110 million, before funding restructuring and capital investment for transformation activities, is also affirmed.
More information on fiscal 2015 guidance, including income statement scenarios underlying the lower and upper ends of the adjusted earnings per share guidance range, can be found in the Investor Relations section of our website at http://www.haemonetics.com.1
FISCAL 2016 PRELIMINARY OUTLOOK
The Company expects to return to a mid-single digit revenue growth rate in fiscal 2016. Included in that outlook is the impact of the continued strengthening of the dollar, which represents a headwind, partly offset by the benefit of a 53-week fiscal year.
The Company expects a return to double digit constant currency adjusted operating income and earnings per share growth rates in fiscal 2016. Including the impact of a greater than 500 basis point headwind attributable to the continued strengthening of the US dollar, the fiscal 2016 outlook is for high single to low double digit, adjusted operating income and earnings per share growth. VCC investments are on track to be completed in fiscal 2016.
Mr. Concannon concluded: “Our Company approaches fiscal 2016 well positioned for success. Our growth drivers, which represent 60% of our revenue, are expected to continue to grow and this growth will be bolstered in fiscal 2016 and beyond by recent contract wins and new product innovations. Our CBMS offering is gaining traction with hospital customers introducing the opportunity for a growth catalyst in the relatively near term.
“We will soon anniversary the setbacks we experienced from the recent market shifts which impacted our North American donor business. The important work that we have undertaken to address our manufacturing cost through VCC and value engineering initiatives will position us well to return our whole blood business to profitable growth as contract opportunities emerge in the future. Mid-single digit revenue and double digit earnings growth rates are achievable and demonstrate that our strategy is working.”
ADJUSTMENTS TO REPORTED EARNINGS
In total, $13 million of pre-tax charges comprised of $12 million of VCC transformation and $1 million of other restructuring activities were excluded from adjusted earnings in the third quarter of fiscal 2015. The Company excluded $18 million of pre-tax integration, restructuring, transformation and transaction costs from adjusted earnings in the third quarter of fiscal 2014.
The Company excluded $51 million of pre-tax charges comprised of $47 million of VCC transformation and $4 million of other restructuring activities from adjusted earnings in the first nine months of fiscal 2015. The Company excluded $70 million of pre-tax integration, restructuring, transformation and transaction costs from adjusted earnings in the same period of fiscal 2014.
The Company also excluded acquisition related amortization expenses from its adjusted operating income and earnings per share. Excluded from third quarter adjusted earnings was acquisition related amortization of $7 million or $0.10 in fiscal 2015 and fiscal 2014.
Excluded from year-to-date adjusted earnings was acquisition related amortization of $23 million in fiscal 2015 and $21 million in fiscal 2014, or $0.30 and $0.29 per share, respectively. For the full fiscal year 2015, acquisition related amortization is expected to approximate $31 million or $0.41 per share.
CONFERENCE CALL
Haemonetics will host a webcast to discuss the third quarter and first nine months of fiscal 2015 results today at 10:00 am Eastern time. Interested parties can participate at: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=5178762.
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve patient care and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.
FORWARD LOOKING STATEMENTS
This release contains forward-looking statements that involve risks and uncertainties, including the effects of disruption from the manufacturing transformation making it more difficult to maintain relationships with employees and timely deliver high quality products, unexpected expenses incurred during our Value Creation and Capture program, technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, demand for whole blood and blood components, product quality, market acceptance, regulatory uncertainties, including in the receipt or timing of regulatory approvals, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers’ ordering patterns including single-source tenders, the effect of industry consolidation as seen in the plasma and blood center markets, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission.
The foregoing list should not be construed as exhaustive.
Forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements. Information set forth in this press release is current as of today and the Company undertakes no duty or obligation to update this information.
1A reconciliation of GAAP to adjusted financial results is included at the end of the financial sections of this press release as well as on the web at http://www.haemonetics.com.
Haemonetics Corporation Financial Summary | ||||||||||
(Data in thousands, except per share data) | ||||||||||
Consolidated Statements of Income for the Third Quarter of FY15 and FY14 | ||||||||||
12/27/2014 | 12/28/2013 | % Inc/(Dec) | ||||||||
As Reported | As Reported | vs Prior Year | ||||||||
(unaudited) | ||||||||||
Net revenues | $ | 231,827 | $ | 242,120 | (4.3)% | |||||
Gross profit | 111,661 | 121,629 | (8.2)% | |||||||
R&D | 10,643 | 14,209 | (25.1)% | |||||||
S,G&A | 82,758 | 89,560 | (7.6)% | |||||||
Operating expenses | 93,401 | 103,769 | (10.0)% | |||||||
Operating income | 18,260 | 17,860 | 2.2% | |||||||
Interest and other expense, net | (2,308 | ) | (2,852 | ) | (19.1)% | |||||
Income before taxes | 15,952 | 15,008 | 6.3% | |||||||
Tax benefit | (36 | ) | (1,282 | ) | (97.2)% | |||||
Net income | $ | 15,988 | $ | 16,290 | (1.9)% | |||||
Net income per common share assuming dilution | $ | 0.31 | $ | 0.31 | —% | |||||
Weighted average number of shares: | ||||||||||
Basic | 51,432 | 51,730 | ||||||||
Diluted | 51,962 | 52,511 | ||||||||
Profit Margins: | Inc/(Dec) vs prior year profit margin % | |||||||||
Gross profit | 48.2 | % | 50.2 | % | (2.0)% | |||||
R&D | 4.6 | % | 5.9 | % | (1.3)% | |||||
S,G&A | 35.7 | % | 37.0 | % | (1.3)% | |||||
Operating income | 7.9 | % | 7.4 | % | 0.5% | |||||
Income before taxes | 6.9 | % | 6.2 | % | 0.7% | |||||
Net income | 6.9 | % | 6.7 | % | 0.2% | |||||
Haemonetics Corporation Financial Summary | ||||||||||
(Data in thousands, except per share data) | ||||||||||
Consolidated Statements of Income for Year-to-Date FY15 and FY14 | ||||||||||
12/27/2014 | 12/28/2013 | % Inc/(Dec) | ||||||||
As Reported | As Reported | vs Prior Year | ||||||||
(unaudited) | ||||||||||
Net revenues | $ | 683,895 | $ | 697,418 | (1.9)% | |||||
Gross profit | 326,053 | 352,924 | (7.6)% | |||||||
R&D | 36,962 | 40,364 | (8.4)% | |||||||
S,G&A | 260,089 | 277,879 | (6.4)% | |||||||
Operating expenses | 297,051 | 318,243 | (6.7)% | |||||||
Operating income | 29,002 | 34,681 | (16.4)% | |||||||
Interest and other expense, net | (7,496 | ) | (8,035 | ) | (6.7)% | |||||
Income before taxes | 21,506 | 26,646 | (19.3)% | |||||||
Tax expense | 1,679 | 1,682 | (0.2)% | |||||||
Net income | $ | 19,827 | $ | 24,964 | (20.6)% | |||||
Net income per common share assuming dilution | $ | 0.38 | $ | 0.48 | (20.8)% | |||||
Weighted average number of shares: | ||||||||||
Basic | 51,521 | 51,485 | ||||||||
Diluted | 52,024 | 52,300 | ||||||||
Profit Margins: | Inc/(Dec) vs prior year profit margin % | |||||||||
Gross profit | 47.7 | % | 50.6 | % | (2.9)% | |||||
R&D | 5.4 | % | 5.8 | % | (0.4)% | |||||
S,G&A | 38.0 | % | 39.8 | % | (1.8)% | |||||
Operating income | 4.2 | % | 5.0 | % | (0.8)% | |||||
Income before taxes | 3.1 | % | 3.8 | % | (0.7)% | |||||
Net income | 2.9 | % | 3.6 | % | (0.7)% | |||||
Revenue Analysis for the Third Quarter FY15 and FY14 | |||||||||||
(Data in thousands) | |||||||||||
Three Months Ended | |||||||||||
12/27/2014 | 12/28/2013 | % Inc/(Dec) | |||||||||
As Reported | As Reported | vs Prior Year | |||||||||
(unaudited) | |||||||||||
Revenues by geography | |||||||||||
United States | $ | 124,766 | $ | 126,752 | (1.6 | )% | |||||
International | 107,061 | 115,368 | (7.2 | )% | |||||||
Net revenues | $ | 231,827 | $ | 242,120 | (4.3 | )% | |||||
Disposable revenues | |||||||||||
Plasma disposables | $ | 83,178 | $ | 76,698 | 8.4 | % | |||||
Blood center disposables | |||||||||||
Platelet | 38,401 | 43,447 | (11.6 | )% | |||||||
Red cell | 10,873 | 9,869 | 10.2 | % | |||||||
Whole blood | 34,182 | 47,342 | (27.8 | )% | |||||||
83,456 | 100,658 | (17.1 | )% | ||||||||
Hospital disposables | |||||||||||
Surgical | 15,608 | 16,807 | (7.1 | )% | |||||||
OrthoPAT | 5,024 | 6,392 | (21.4 | )% | |||||||
Diagnostics | 10,890 | 8,565 | 27.1 | % | |||||||
31,522 | 31,764 | (0.8 | )% | ||||||||
Total disposables revenues | 198,156 | 209,120 | (5.2 | )% | |||||||
Software solutions | 18,211 | 17,603 | 3.5 | % | |||||||
Equipment & other | 15,460 | 15,397 | 0.4 | % | |||||||
Net revenues | $ | 231,827 | $ | 242,120 | (4.3 | )% | |||||
Revenue Analysis for Year-to-Date FY15 and FY14 | |||||||||||
(Data in thousands) | |||||||||||
Nine Months Ended | |||||||||||
12/27/2014 | 12/28/2013 | % Inc/(Dec) | |||||||||
As Reported | As Reported | vs Prior Year | |||||||||
(unaudited) | |||||||||||
Revenues by geography | |||||||||||
United States | $ | 369,921 | $ | 374,559 | (1.2 | )% | |||||
International | 313,974 | 322,859 | (2.8 | )% | |||||||
Net revenues | $ | 683,895 | $ | 697,418 | (1.9 | )% | |||||
Disposable revenues | |||||||||||
Plasma disposables | $ | 242,760 | $ | 217,768 | 11.5 | % | |||||
Blood center disposables | |||||||||||
Platelet | 115,941 | 117,778 | (1.6 | )% | |||||||
Red cell | 31,296 | 30,098 | 4.0 | % | |||||||
Whole blood | 105,870 | 145,879 | (27.4 | )% | |||||||
253,107 | 293,755 | (13.8 | )% | ||||||||
Hospital disposables | |||||||||||
Surgical | 46,889 | 49,247 | (4.8 | )% | |||||||
OrthoPAT | 15,302 | 18,973 | (19.3 | )% | |||||||
Diagnostics | 30,535 | 24,144 | 26.5 | % | |||||||
92,726 | 92,364 | 0.4 | % | ||||||||
Total disposables revenues | 588,593 | 603,887 | (2.5 | )% | |||||||
Software solutions | 54,094 | 51,469 | 5.1 | % | |||||||
Equipment & other | 41,208 | 42,062 | (2.0 | )% | |||||||
Net revenues | $ | 683,895 | $ | 697,418 | (1.9 | )% | |||||
Consolidated Balance Sheets | |||||||||
(Data in thousands) | |||||||||
As of | |||||||||
12/27/2014 | 3/29/2014 | ||||||||
(unaudited) | |||||||||
Assets | |||||||||
Cash and cash equivalents | $ | 125,200 | $ | 192,469 | |||||
Accounts receivable, net | 143,635 | 164,603 | |||||||
Inventories, net | 212,493 | 197,661 | |||||||
Other current assets | 66,157 | 68,243 | |||||||
Total current assets | 547,485 | 622,976 | |||||||
Property, plant & equipment, net | 323,491 | 271,437 | |||||||
Other assets | 600,823 | 619,765 | |||||||
Total assets | $ | 1,471,799 | $ | 1,514,178 | |||||
Liabilities & Stockholders' Equity | |||||||||
Short-term debt & current maturities | $ | 7,748 | $ | 45,630 | |||||
Other current liabilities | 154,246 | 171,298 | |||||||
Total current liabilities | 161,994 | 216,928 | |||||||
Long-term debt | 421,006 | 392,057 | |||||||
Other long-term liabilities | 54,891 | 67,305 | |||||||
Stockholders' equity | 833,908 | 837,888 | |||||||
Total liabilities & stockholders' equity | $ | 1,471,799 | $ | 1,514,178 | |||||
Free Cash Flow Reconciliation | ||||||||
(Data in thousands) | ||||||||
Three Months Ended | ||||||||
12/27/2014 | 12/28/2013 | |||||||
(unaudited) | ||||||||
GAAP cash flow from operations | $ | 26,851 | $ | 45,291 | ||||
Capital expenditures | (29,658 | ) | (15,519 | ) | ||||
Proceeds from sale of property, plant & equipment | 10 | (445 | ) | |||||
Net investment in property, plant & equipment | (29,648 | ) | (15,964 | ) | ||||
Free cash flow after restructuring and transformation costs | (2,797 | ) | 29,327 | |||||
Restructuring and transformation costs | 20,995 | 13,124 | ||||||
Tax benefit on restructuring and transformation costs | (6,521 | ) | — | |||||
Capital expenditures on VCC initiatives | 13,155 | 4,075 | ||||||
Free cash flow before restructuring, transformation costs and VCC capital expenditures | $ | 24,832 | $ | 46,526 | ||||
Nine Months Ended | ||||||||
12/27/2014 | 12/28/2013 | |||||||
(unaudited) | ||||||||
GAAP cash flow from operations | $ | 71,831 | $ | 88,053 | ||||
Capital expenditure | (100,530 | ) | (43,721 | ) | ||||
Proceeds from sale of property, plant & equipment | 387 | 197 | ||||||
Net investment in property, plant & equipment | (100,143 | ) | (43,524 | ) | ||||
Free cash flow after restructuring and transformation costs | (28,312 | ) | 44,529 | |||||
Restructuring and transformation costs | 54,819 | 44,629 | ||||||
Tax benefit on restructuring and transformation costs | (18,079 | ) | — | |||||
Capital expenditures on VCC initiatives | 44,725 | 5,920 | ||||||
Free cash flow before restructuring, transformation costs and VCC capital expenditures | $ | 53,153 | $ | 95,078 | ||||
Haemonetics Corporation Financial Summary | ||||
Reconciliation of Non-GAAP Measures | ||||
Haemonetics has presented supplemental non-GAAP financial measures as part of this earnings release. A reconciliation is provided below that reconciles each non-GAAP financial measure with the most comparable GAAP measure. The presentation of non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the most directly comparable GAAP measures. There are material limitations to the usefulness of non-GAAP measures on a standalone basis, including the lack of comparability to the GAAP financial results of other companies.
These measures are used by management to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are established based upon these non-GAAP measures. In the reconciliations below we have removed restructuring, transformation and other costs from our GAAP expenses. Our restructuring and transformation costs for the periods reported are principally related to:
• | Value Creation & Capture (VCC): employee severance and retention, product line transfer costs, accelerated depreciation and other costs associated with these initiatives, principally our manufacturing network optimization, but also including commercial excellence, productivity and other operating initiatives. |
• | Whole Blood Acquisition: restructuring, integration and other transformation costs related to the August 1, 2012 acquisition of Pall's Transfusion Medicine Business. |
• | In Process Research and Development: charges relate to the acquisition of certain technology and manufacturing rights to be used in a next generation device and related costs. |
Restructuring and transformation costs also include costs related to activities launched prior to the VCC initiatives designed to align our cost structure with strategic and operational priorities. Costs incurred under these programs are reflected in "Productivity and operational initiatives" within the tables below.
We are reporting adjusted earnings before deal amortization, in addition to restructuring and transformation costs.
We believe this information is useful to investors because it allows for an evaluation of the Company with a focus on the performance of our core operations.
Reconciliation of Non-GAAP Measures for the Third Quarter of FY15 and FY14 | |||||||
(Data in thousands) | |||||||
Three Months Ended | |||||||
12/27/2014 | 12/28/2013 | ||||||
(unaudited) | |||||||
Non-GAAP gross profit | |||||||
GAAP gross profit | $ | 111,661 | $ | 121,629 | |||
Restructuring and transformation costs | 2,459 | 2,593 | |||||
Non-GAAP gross profit | $ | 114,120 | $ | 124,222 | |||
Non-GAAP R&D | |||||||
GAAP R&D | $ | 10,643 | $ | 14,209 | |||
Restructuring and transformation costs | (627 | ) | (2,002 | ) | |||
Non-GAAP R&D | $ | 10,016 | $ | 12,207 | |||
Non-GAAP S,G&A | |||||||
GAAP S,G&A | $ | 82,758 | $ | 89,560 | |||
Restructuring and transformation costs | (9,579 | ) | (12,599 | ) | |||
Deal amortization | (7,468 | ) | (7,436 | ) | |||
Non-GAAP S,G&A | $ | 65,711 | $ | 69,525 | |||
Non-GAAP operating expenses | |||||||
GAAP operating expenses | $ | 93,401 | $ | 103,769 | |||
Restructuring and transformation costs | (10,206 | ) | (14,601 | ) | |||
Deal amortization | (7,468 | ) | (7,436 | ) | |||
Non-GAAP operating expenses | $ | 75,727 | $ | 81,732 | |||
Non-GAAP operating income | |||||||
GAAP operating income | $ | 18,260 | $ | 17,860 | |||
Restructuring and transformation costs | 12,665 | 17,194 | |||||
Deal amortization | 7,468 | 7,436 | |||||
Non-GAAP operating income | $ | 38,393 | $ | 42,490 | |||
Non-GAAP other expense | |||||||
GAAP other expense | $ | 2,308 | $ | 2,852 | |||
Restructuring and transformation costs | (244 | ) | (306 | ) | |||
Non-GAAP other expense | $ | 2,064 | $ | 2,546 | |||
Non-GAAP income before taxes | |||||||
GAAP income before taxes | $ | 15,952 | $ | 15,008 | |||
Restructuring and transformation costs | 12,909 | 17,500 | |||||
Deal amortization | 7,468 | 7,436 | |||||
Non-GAAP income before taxes | $ | 36,329 | $ | 39,944 | |||
Non-GAAP net income | |||||||
GAAP net income | $ | 15,988 | $ | 16,290 | |||
Restructuring and transformation costs | 12,909 | 17,500 | |||||
Deal amortization | 7,468 | 7,436 | |||||
Tax benefit associated with non-GAAP adjustments | (8,900 | ) | (9,106 | ) | |||
Non-GAAP net income | $ | 27,465 | $ | 32,120 | |||
Non-GAAP net income per common share assuming dilution | |||||||
GAAP net income per common share | $ | 0.31 | $ | 0.31 | |||
Non-GAAP items after tax per common share assuming dilution | $ | 0.22 | $ | 0.30 | |||
Non-GAAP net income per common share assuming dilution | $ | 0.53 | $ | 0.61 | |||
Presented below are additional Constant Currency performance measures. We measure different components of our business at constant currency. We believe this information is useful for investors because it allows for an evaluation of the Company without the effect of changes in foreign exchange rates. These results convert our local foreign currency operating results to the US Dollar at constant exchange rates of 0.833 Euro to 1.00 US Dollar and 110 Yen to 1.00 US Dollar. They also exclude the results of our foreign currency hedging program described in Note 7 to our consolidated financial statements in our Form 10-K. | |||||||
Three Months Ended | |||||||
12/27/2014 | 12/28/2013 | ||||||
(unaudited) | |||||||
Non-GAAP revenues | |||||||
GAAP revenue | $ | 231,827 | $ | 242,120 | |||
Foreign currency effects | (5,247 | ) | (12,265 | ) | |||
Non-GAAP revenue - constant currency | $ | 226,580 | $ | 229,855 | |||
Non-GAAP net income | |||||||
Non-GAAP net income, adjusted for restructuring and transformation costs and deal amortization | $ | 27,465 | $ | 32,120 | |||
Foreign currency effects | (4,474 | ) | (5,189 | ) | |||
Income tax associated with foreign currency effects | 1,091 | 1,016 | |||||
Non-GAAP net income - constant currency | $ | 24,082 | $ | 27,947 | |||
Non-GAAP net income per common share assuming dilution | |||||||
Non-GAAP net income per common share assuming dilution, adjusted for restructuring and transformation costs and deal amortization | $ | 0.53 | $ | 0.61 | |||
Foreign currency effects after tax per common share assuming dilution | $ | (0.07 | ) | $ | (0.08 | ) | |
Non-GAAP net income per common share assuming dilution - constant currency | $ | 0.46 | $ | 0.53 | |||
Reconciliation of Non-GAAP Measures for FY15 and FY14 | |||||||
(Data in thousands) | |||||||
Nine Months Ended | |||||||
12/27/2014 | 12/28/2013 | ||||||
(unaudited) | |||||||
Non-GAAP gross profit | |||||||
GAAP gross profit | $ | 326,053 | $ | 352,924 | |||
Restructuring and transformation costs | 7,746 | 8,193 | |||||
Non-GAAP gross profit | $ | 333,799 | $ | 361,117 | |||
Non-GAAP R&D | |||||||
GAAP R&D | $ | 36,962 | $ | 40,364 | |||
Restructuring and transformation costs | (5,207 | ) | (7,307 | ) | |||
Non-GAAP R&D | $ | 31,755 | $ | 33,057 | |||
Non-GAAP S,G&A | |||||||
GAAP S,G&A | $ | 260,089 | $ | 277,879 | |||
Restructuring and transformation costs | (37,589 | ) | (53,775 | ) | |||
Deal amortization | (22,769 | ) | (21,048 | ) | |||
Non-GAAP S,G&A | $ | 199,731 | $ | 203,056 | |||
Non-GAAP operating expenses | |||||||
GAAP operating expenses | $ | 297,051 | $ | 318,243 | |||
Restructuring and transformation costs | (42,796 | ) | (61,082 | ) | |||
Deal amortization | (22,769 | ) | (21,048 | ) | |||
Non-GAAP operating expenses | $ | 231,486 | $ | 236,113 | |||
Non-GAAP operating income | |||||||
GAAP operating income | $ | 29,002 | $ | 34,681 | |||
Restructuring and transformation costs | 50,542 | 69,274 | |||||
Deal amortization | 22,769 | 21,048 | |||||
Non-GAAP operating income | $ | 102,313 | $ | 125,003 | |||
Non-GAAP other expense | |||||||
GAAP other expense | $ | 7,496 | $ | 8,035 | |||
Restructuring and transformation costs | (705 | ) | (616 | ) | |||
Non-GAAP other expense | $ | 6,791 | $ | 7,419 | |||
Non-GAAP income before taxes | |||||||
GAAP income before taxes | $ | 21,506 | $ | 26,646 | |||
Restructuring and transformation costs | 51,247 | 69,890 | |||||
Deal amortization | 22,769 | 21,048 | |||||
Non-GAAP income before taxes | $ | 95,522 | $ | 117,584 | |||
Non-GAAP net income | |||||||
GAAP net income | $ | 19,827 | $ | 24,964 | |||
Restructuring and transformation costs | 51,247 | 69,890 | |||||
Deal amortization | 22,769 | 21,048 | |||||
Tax benefit associated with non-GAAP adjustments | (22,288 | ) | (25,622 | ) | |||
Non-GAAP net income | $ | 71,555 | $ | 90,280 | |||
Non-GAAP net income per common share assuming dilution | |||||||
GAAP net income per common share | $ | 0.38 | $ | 0.48 | |||
Non-GAAP items after tax per common share assuming dilution | $ | 1.00 | $ | 1.25 | |||
Non-GAAP net income per common share assuming dilution | $ | 1.38 | $ | 1.73 | |||
Presented below are additional Constant Currency performance measures. We measure different components of our business at constant currency. We believe this information is useful for investors because it allows for an evaluation of the Company without the effect of changes in foreign exchange rates. These results convert our local foreign currency operating results to the US Dollar at constant exchange rates of 0.833 Euro to 1.00 US Dollar and 110 Yen to 1.00 US Dollar. They also exclude the results of our foreign currency hedging program described in Note 7 to our consolidated financial statements in our Form 10-K. | |||||||
Nine Months Ended | |||||||
12/27/2014 | 12/28/2013 | ||||||
(unaudited) | |||||||
Non-GAAP revenues | |||||||
GAAP revenue | $ | 683,895 | $ | 697,418 | |||
Foreign currency effects | (23,216 | ) | (32,655 | ) | |||
Non-GAAP revenue - constant currency | $ | 660,679 | $ | 664,763 | |||
Non-GAAP net income | |||||||
Non-GAAP net income, adjusted for restructuring and transformation costs and deal amortization | $ | 71,555 | $ | 90,280 | |||
Foreign currency effects | (10,390 | ) | (15,740 | ) | |||
Income tax associated with foreign currency effects | 2,607 | 3,650 | |||||
Non-GAAP net income - constant currency | $ | 63,772 | $ | 78,190 | |||
Non-GAAP net income per common share assuming dilution | |||||||
Non-GAAP net income per common share assuming dilution, adjusted for restructuring and transformation costs and deal amortization | $ | 1.38 | $ | 1.73 | |||
Foreign currency effects after tax per common share assuming dilution | $ | (0.15 | ) | $ | (0.23 | ) | |
Non-GAAP net income per common share assuming dilution - constant currency | $ | 1.23 | $ | 1.50 | |||
Restructuring, Transformation and Other Costs (Data in thousands) GAAP results include the following items which are excluded from adjusted results. | |||||||
Three Months Ended | |||||||
12/27/2014 | 12/28/2013 | ||||||
(unaudited) | |||||||
Manufacturing network optimization | $ | 7,155 | $ | 11,332 | |||
Commercial excellence initiatives | 1,413 | 1,280 | |||||
Productivity and operational initiatives | 1,863 | 220 | |||||
Accelerated depreciation, asset write-down and other non-cash items | 1,686 | 2,131 | |||||
Whole blood acquisition and integration | — | 734 | |||||
In process research and development and related costs | 326 | 1,153 | |||||
Market-based stock compensation | 466 | 650 | |||||
Total restructuring, transformation and other costs | $ | 12,909 | $ | 17,500 | |||
Nine Months Ended | |||||||
12/27/2014 | 12/28/2013 | ||||||
(unaudited) | |||||||
Manufacturing network optimization | $ | 29,919 | $ | 39,226 | |||
Commercial excellence initiatives | 7,181 | 5,445 | |||||
Productivity and operational initiatives | 6,592 | 1,334 | |||||
Accelerated depreciation, asset write-down and other non-cash items | 3,399 | 6,589 | |||||
Whole blood acquisition and integration | — | 10,967 | |||||
In process research and development and related costs | 2,122 | 5,129 | |||||
Market-based stock compensation | 2,034 | 1,200 | |||||
Total restructuring, transformation and other costs | $ | 51,247 | $ | 69,890 | |||
Deal Amortization (Data in thousands) GAAP results include the following item which is excluded from adjusted results. | |||||||
Three Months Ended | |||||||
12/27/2014 | 12/28/2013 | ||||||
(unaudited) | |||||||
Deal amortization | $ | 7,468 | $ | 7,436 | |||
Nine Months Ended | |||||||
12/27/2014 | 12/28/2013 | ||||||
(unaudited) | |||||||
Deal amortization | $ | 22,769 | $ | 21,048 | |||